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Morphine and related compounds are the ﬁrst line of therapy in the treatment of moderate to severe pain.
Over time, individuals taking opioids can develop an increasing sensitivity to noxious stimuli, even evolv-
ing into a painful response to previously non-noxious stimuli (opioid-induced hyperalgesia; OIH). The
mechanism underlying OIH is not well understood although complex intracellular neural mechanisms,
including opioid receptor desensitization and down-regulation, are believed to be major mechanisms
underlying OIH. However, OIH may also be associated with changes in gene expression. A growing body
of evidence suggests that cellular exposure to mu agonists upregulate chemokines/receptors and recent
work from our laboratory implicates chemokine upregulation in a variety of neuropathic pain behaviors.
Here we characterized the degree to which chemokines/receptors signaling is increased in primary affer-
ent neurons of the dorsal root ganglion (DRG) following chronic morphine sulfate treatment and corre-
lated these changes with tactile hyperalgesic behavior in rodents. We demonstrate that mRNA expression
of the chemokine, stromal-derived factor-1 (SDF1/CXCL12) is upregulated following morphine treatment
in sensory neurons of the rat. The release of SDF1 was found to be constitutive when compared with the
activity dependent release of the C–C chemokine, monocyte chemoattractant protein-1 (MCP1/CCL2) in a
line of F11 neuroblastoma-sensory neuron hybrid cells. We further determined that there is pronounced
CXCR4 expression in satellite glial cells and following morphine treatment, increased functional CXCR4
expression in sensory neurons of the DRG. Moreover, intraperitoneal administration of the speciﬁc CXCR4
antagonist, AMD3100, completely reversed OIH in the rat. Taken together; the data suggest that opioid-
induced SDF1/CXCR4 signaling is central to the development of long lasting OIH and that receptor antag-
onists represent a promising novel approach to the management of the side effects associated with the
use of opioids for chronic pain management.
 2010 Elsevier Inc. All rights reserved.1. Introduction
Opioids such as morphine currently represent the best option
for the management of moderate to severe trauma induced, peri-
operative and cancer pain. Opioid compounds are also increasingly
being used for non-cancer associated chronic pathological pain.
However, prolonged administration of opioids is associated with
signiﬁcant problems including the development of anti-nocicep-
tive tolerance, wherein higher doses of the drug are required over
time to elicit the same degree of analgesia. Repeated administra-
tion of higher doses of morphine or fentanyl also results in increas-
ing pain sensitivity, a syndrome clinically known as opioid-induced
hyperalgesia (OIH) (Angst et al., 2003; Arner et al., 1988; Singlall rights reserved.
esthesia, Program in Medical
te, Indiana University, India-et al., 2007). This increased pain is usually experienced at different
locations from the original site of injury (Ossipov et al., 2004).
While it is thought that opioids modulate tactile hyperalgesia
solely by acting at neuronal opioid receptors, administration of
chronic morphine is also known to induce a rapid increase in the
expression of the proinﬂammatory cytokines such as TNFa, IL1b
and IL-6 in a number of cell types within the nervous system
(Johnston et al., 2004). These proinﬂammatory cytokines are
powerful pain enhancing proteins that may, in turn, suppress acute
opioid analgesia and contribute to the apparent loss of opioid
analgesia upon repeated opioid administration (‘‘tolerance’’)
(Hutchinson et al., 2008). The family of pro-nociceptive cytokines
includes chemotactic cytokines (chemokines). Proalgesic effects
of chemokines have been implicated in both acute and chronic
tactile hyperalgesic behavior (Abbadie et al., 2003; Bhangoo
et al., 2007a,b; Johnston et al., 2004; Jung et al., 2009; Menetski
et al., 2007; Milligan et al., 2004; Oh et al., 2001; Wang et al.,
2008; White et al., 2005; Xie et al., 2006). However, the degree
to which chronic morphine treatment alters gene expression of
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syndromes such as OIH is unknown.
Effects of opioids on chemokine receptor expression are poten-
tially important determinants of HIV-1 infection rates among
intravenous drug users as the chemokine receptors CCR5 and
CXCR4 are coreceptors for the HIV-1 virus coat protein, gp120. To
this end a number of studies using chronic morphine or the selec-
tive l opioid agonist, [D-Ala2, N-MePhe4, Gly-ol]-enkephalin
(DAMGO) produce increased expression of monocyte chemoattrac-
tant protein-1 (MCP1/CCL2), regulated upon activation normal T-
cell expressed and secreted (RANTES/CCL5), and their respective
receptors, CCR2 and CCR5, in astrocytes and neurons via largely
unknown mechanisms (Avdoshina et al., 2010; Mahajan et al.,
2005; Rock et al., 2006). A similar study demonstrated that DAM-
GO substantially increased the expression of both CCR5 and CXCR4
in leukocytes (Steele et al., 2003). Taken together, these observa-
tions raise the possibility that repeated exposure to opioids and
subsequent increases in chemokine receptor signaling might also
be central to OIH.
We now demonstrate that many nociceptive neurons express
functional receptors for a number of chemokines following sys-
temic injection of morphine. Chemokine receptor signaling via
the CXCR4 receptor may be central to OIH as the administration
of the speciﬁc CXCR4 receptor antagonist, AMD3100, transiently
reversed OIH in rats. Collectively, the data suggest that chemokine
receptor antagonists represent a promising novel approach to the
management of the side effects associated with long term opioids
for chronic pain control.
2. Methods
2.1. Animals
Pathogen-free, adult female Sprague–Dawley rats (150–200 g;
Harlan Laboratories, Madison, WI) were housed in temperature
(23 ± 3 C) and light (12-h light:12-h dark cycle; lights on at
07:00 h) controlled rooms with standard rodent chow and water
available ad libitum. Experiments were performed during the light
cycle. These experiments were approved by the Institutional Ani-
mal Care and Use Committee of Loyola University, Chicago and
Indiana University/Purdue University in Indianapolis. All proce-
dures were conducted in accordance with the Guide for Care and
Use of Laboratory Animals published by the National Institutes of
Health and the Ethical Guidelines of the International Association
for the Study of Pain. All animals were randomly assigned to either
treatment or control groups.Fig. 1. Repeated morphine treatment paradigm. Animals underwent baseline testing fo
morphine (10 mg/kg) for 5 days. Behavioral testing that occurred during the 5 days of inje
the injection period, behavior was conducted on animals for up to 28 days following
AMD3100, occurred 5 days after the last morphine injection (PID5).2.1.1. Drugs and method of administration
The drugs, morphine sulfate salt and the bicyclam, AMD3100,
were employed in this study. Morphine sulfate salt and
AMD3100 were purchased from NIDA Drug Supply Program (Rock-
ville, MD) and Sigma–Aldrich (St. Louis, MO), respectively. All
drugs were freshly prepared in saline on the day of the experiment.
Morphine sulfate- and vehicle-treated groups were given intra-
peritoneal (i.p.) injections once daily for 5 days of 10 mg/kg or sal-
ine (vehicle). After tactile hyperalgesia was established, animals
were given an i.p. injection of AMD3100 (10 mg/kg) (Fig. 1). Previ-
ous nociceptive behavioral studies from our laboratory using
AMD3100 at doses of (1, 5, 10, and 25 mg/kg) observed: no reversal
of effect with 1 mg/kg, partial inconsistent effect with 5 mg/kg,
reversal with 10 mg/kg, and reversal with side effects at 25 mg/
kg (unpublished observations). Therefore, 10 mg/kg AMD3100
was selected for these studies.
2.2. Behavioral assessment
von Frey ﬁlaments were used to test mechanical sensitivity be-
fore, during and after cessation of morphine sulfate administration.
Prior to initial von Frey tactile testing, all rodents were habituated
to testing chambers for at least 2 days. Animals were tested for
baseline responses (BL) at least two times before undergoing the
repeated morphine sulfate treatment (10 mg/kg, i.p. daily).
Mechanical testing with von Frey ﬁlaments during the morphine
sulfate dosing paradigm was limited to injection day (ID) 3. Behav-
ioral assessment on ID3 occurred 18–20 h after the ID2 morphine
administration and before ID3 morphine or vehicle treatment
(Fig. 1). Additional behavioral assessment following drug or vehicle
administration occurred on post-injection day (PID) 1, 2, 3, 7, 14,
21, and 28. All behavioral testing was performed by laboratory
assistants who were blinded to the experimental conditions and
unfamiliar with the experimental aims.
The incidence of foot withdrawal in response to mechanical
indentation of the plantar surface of each hind paw was measured
with a von Frey ﬁlament capable of exerting forces of 10, 20, 40, 60,
80 and 120 mN. These probes exhibit a uniform tip diameter
(0.2 mm) and were applied to 6 designated loci distributed over
the plantar surface of the foot (Ma et al., 2003). These six spots
are representative of the distal nerve distributions of saphenous,
tibial and sural nerves (medial to lateral) in the glabrous hind
paw. During each test, the rodent was placed in a transparent plas-
tic cage with a ﬂoor of wire with 1  1 cm openings. The cage is
elevated so that stimulation can be applied to each hind foot from
beneath the rodent. The ﬁlaments were applied in order of ascend-r 2–3 days prior to the start of injections. Rats received once daily i.p. injections of
ctions (ID) were carried out 18–20 hours after the last morphine injection. Following
the last morphine injection (PID). Behavioral testing with the CXCR4 antagonist,
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each locus. The duration of each stimulus was approximately 1 s
and the inter-stimulus interval was approximately 10–15 s. The
incidence of foot withdrawal is expressed as a percentage of the
six applications of each stimulus and the percentage of withdraw-
als was then plotted as a function of force (Bhangoo et al., 2007a;
Ma et al., 2003). The von Frey withdrawal threshold was deﬁned
as the force that evoked a minimum detectable withdrawal ob-
served on 50% of the tests given at the same force level. For cases
in which none of the speciﬁc ﬁlaments used evoked withdrawals
on exactly 50% of the tests, linear interpolation was used to deﬁne
the threshold.
2.3. Tissue processing and immunocytochemistry for neural tissue
Morphine or control treatments rats’ lumbar (L3–L6) DRG tissue
was collected after animals were sacriﬁced and transcardially-per-
fused with saline followed by ﬁxative. Fixed tissue was then
embedded for sectioning and processed using immunocytochemi-
cal methodologies commonly used in this laboratory (Bhangoo
et al., 2007a). Tissue sections from L4 and L5 were used in immuno-
cytochemical experiments. Primary antisera used was the anti-
CXCR4 rat monoclonal antibody, 2B11 (1:20,000 dilution; BD Bio-
sciences, San Jose, CA) which binds to both human and mouse
CXCR4 (Forster et al., 1998; Schabath et al., 1999). After primary
incubation, slides were incubated in secondary antibodies (anti-
rat made in horse conjugated to CY3, Jackson ImmunoResearch,
West Grove, PA).
2.4. Preparation of acutely dissociated dorsal root ganglion neurons
The L1–L6 DRGs were acutely dissociated using methods de-
scribed by Ma and LaMotte (2005). Brieﬂy, L1–L6 DRGs were re-
moved from naïve or morphine-treated animals 4–6 days
following the last morphine injection. The DRGs were treated with
collagenase A and collagenase D in HBSS for 20 min (1 mg/ml;
Roche Applied Science, Indianapolis, IN), followed by treatment
with papain (30 U/ml, Worthington Biochemical, Lakewood, NJ)
in HBSS containing 0.5 mM EDTA and cysteine at 35 C. The cells
were then dissociated via mechanical trituration in culture media
containing 1 mg/ml bovine serum albumin and trypsin inhibitor
(1 mg/ml, Sigma, St. Louis, MO). The culture media was Ham’s F-
12 mixture, supplemented with 10% fetal bovine serum, penicillin
and streptomycin (100 lg/ml and 100 U/ml) and N2 (Life Technol-
ogies). The cells were then plated on coverslips coated with poly-L
lysine and laminin (1 mg/ml) and incubated for 2–3 h before more
culture media was added to the wells. The cells were then allowed
to sit undisturbed for 12–15 h to adhere at 37 C (with 5% CO2).
2.5. Intracellular Ca2+ imaging
The dissociated DRG cells were loaded with fura-2 AM (3 lM,
Molecular Probes/Invitrogen Corporation, Carlsbad, CA) for
25 min at room temperature in a balanced sterile salt solution
(BSS) [NaCl (140 mM), Hepes (10 mM), CaCl2 (2 mM), MgCl2
(1 mM), glucose (10 mM), KCl (5 mM)]. The cells were rinsed with
the BSS and mounted onto a chamber that was placed onto the in-
verted microscope. Intracellular calcium was measured by digital
video microﬂuorometry with an intensiﬁed CCD camera coupled
to a microscope and MetaFluor software (Molecular Devices
Corporation, Downington, PA). Cells were illuminated with a
150 W xenon arc lamp, and the excitation wavelengths of the
fura-2 (340/380 nm) were selected by a ﬁlter changer. Sterile solu-
tion was applied to cells prior to chemokine application, any cells
that responded to buffer alone were not used in chemokine
responsive counts. Chemokines were applied directly into thecoverslip bathing solution. If no response was seen within 1 min,
the chemokine was washed out. For all experiments, MCP1, SDF1,
regulated upon activation, normal T-cell expressed and secreted
(RANTES/CCL5), and interferon-gamma-induced protein (IP10/
CXCL10) were added to the cells in random order, after which cap-
saicin (3 nM), high K+ (50 lM) and ATP (3 nM) were added. The
chemokines used were purchased from R&D Systems (Minneapolis,
MN; <1.0 endotoxin per 1 lg of the protein by the LAL method),
and all were used at a concentration of 100 nM to ensure maximal
activation (Bhangoo et al., 2007a,b). Chemokines were reconsti-
tuted in sterile 0.1%BSA/PBS, and aliquots were stored at 20 C.
Calcium imaging traces were analyzed by two independent analyz-
ers and only responses that were in agreement between two indi-
viduals were used in the counts.
2.6. In situ hybridization
In situ hybridization histochemistry for chemokine receptors
was performed using digoxigenin-labeled riboprobes. Treated
and non-treated rodents were sacriﬁced using carbon monoxide.
Lumbar DRGs from the injected and control animals were rapidly
removed, embedded in OCT compound (Tissue Tek, Ted Pella,
Inc., Redding, CA) and frozen. L4 and L5 DRG sections were cut seri-
ally at 12 lm. The SDF1 probes were generated as described previ-
ously (Lu et al., 2002). Signals were visualized by using NBT/BCIP
reagents (Roche Applied Science, Indianapolis, IN) in the dark for
2–20 h depending upon the abundance of the RNA. The in situ im-
age was captured using a Retiga EX charge-coupled device camera
(Q-imaging, Burnaby, BC).
2.7. Plasmid construction
To make chemokine-ﬂuorescent protein fusion constructs,
MCP1 and SDF1-a protein coding sequence was cloned into pEG-
FP-N1 or pmCherry-N1 (Clontech).
2.8. F11 culture conditions
F11 cells (a mouse N18TG2 neuroblastoma  rat DRG sensory
neuron hybrid cell line) were grown as monolayers either in 100-
mm plastic dishes under 5% CO2 in Ham’s F-12 medium supple-
mented with 20% fetal bovine serum (Hyclone), 100 pM hypoxan-
thine/1 pM aminopterin/l2 pA4 thymidine, and 50 IU/ml of
penicillin/streptomycin. Cells were fed every other day for several
days preceding an experiment with Ham’s F-12 medium supple-
mented with 1% fetal bovine serum, 50 ng/ml of NGF, 2 pM retinoic
acid, 0.5 mM dibutyryl cyclic AMP, 10 pM3-isobutyl-1-methylxan-
thine (IBMX), a 1:500 dilution of 2.5 mg/ml of bovine insulin, a
1:100 dilution of 10 mg/ml of transferrin, and 50 IU/ml of penicil-
lin/streptomycin.
2.9. Enzyme-linked immunosorbent assay (ELISA)
Constitutive and regulated release of MCP1-RFP (mCherry) and
SDF1-RFP (mCherry) was measured by sandwich ELISA. F11 DRG
neuronal cells were transfected with MCP1-RFP or SDF1-RFP.
Twenty-four hours after the transfection, cells were placed under
differentiating conditions and allowed to differentiate for 48 h.
When cells were fully differentiated, culture medium was replaced
with balanced salt solution (BSS) containing either 5 mM (normal)
or 50 mM KCl (depolarizing). Normal BSS (145 mM NaCl, 5 mM
KCl, 2 mM CaCl2, 1 mM MgCl2) and depolarizing BSS (100 mM
NaCl, 50 mM KCl, 2 mM CaCl2, 1 mMMgCl2) had the same osmolar-
ity. After 30 min, released MCP1-RFP or SDF1-RFP was measured
from supernatant by sandwich ELISA. A polyclonal anti-RFP anti-
body (Abcam ab34771) was used as the capture antibody
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ing antibodies: for SDF1, a mouse monoclonal anti-SDF1 antibody
(Santa Cruz sc-74271); for MCP1, a goat polyclonal antibody (Santa
Cruz sc-1785).
2.10. Statistics
Data for sandwich ELISA were presented as mean ± SEM and
analyzed by one-way ANOVA followed by Newman–Keuls multiple
comparison tests. Prism 5 (GraphPad, LaJolla, CA) was used to
determine the statistical signiﬁcance of differences in the mean
threshold forces for foot withdrawal to punctate indentation as a
function of time and between experimental groups by means of re-
peated measures analyses of variance (RMANOVA) followed by
post hoc pairwise comparisons (Tukey method). Statistical signiﬁ-
cance was set at p < 0.05. GraphPad Software (LaJolla, CA) was used
to determine the statistical signiﬁcance of differences in calcium
response among naïve and treatment groups using v2 test with
Yates correction with p < 0.05 set as statistical signiﬁcance.
3. Results
3.1. Repeated morphine treatment leads to tactile hyperalgesia
Tactile hyperalgesia as measured by von Frey ﬁlaments is a
characteristic behavioral response that develops in rodents follow-
ing repeated administration of morphine (Celerier et al., 2000; Gar-
dell et al., 2002). Our behavioral assessment of tactile hyperalgesia
was performed prior to the start of the injection paradigm, during
the 5 day dosing regimen, and for 28 days following the repeated
morphine treatment paradigm (Fig. 1). In our experiments, the
mean paw withdrawal threshold (PWT) of the tested hind paws
exhibited a decrease after only two daily morphine injections rel-
ative to pre-injection baseline PWT (ID3; 70.5 ± 2.1–
35.1 ± 2.9 mN; n = 12; p < 0.0001). Statistically signiﬁcant de-
creases in PWT were maintained until at least PID28 (Fig. 2). The
changes in PWT observed at ID3 suggest that this nociceptive
behavior is unafﬁliated with morphine withdrawal signs such asFig. 2. Repeated morphine treatment (10 mg/kg for 5 days) results in the developmen
behavior persists for at least 28 days following the last morphine injection. ID, injection
baseline).jumping or wet dog shakes. Opioid withdrawal behaviors were ob-
served between 24 and 48 h following the last morphine injection
(data not shown). Alterations in the paw withdrawal latency
evoked by thermal stimulation were not observed with this dosing
paradigm (data not shown).3.2. Repeated morphine treatment decreases CXCR4 immunoreactivity
in the rat DRG
The CXCR4 antibody binds the N-glycosylation site g1 of human
CXCR4. Although this site does not inﬂuence HIV-1 coreceptor
function (Huskens et al., 2007), this antibody is an effective neu-
tralizing antibody in tumor formation and angiogenesis (Katoh
et al., 2010). In the adult rat dorsal root ganglia (DRG), CXCR4
expression is largely limited to presumptive non-myelinating sa-
tellite glial cells (SGCs) of the DRG based on anatomical locale
(Fig. 3A). In addition to the SGCs, an occasional neuron was also ob-
served to express the CXCR4. This expression pattern in the DRG
coincides with CXCR4 mRNA expression pattern seen previously
(Bhangoo et al., 2007). By comparison, very few CXCR4-immunore-
active, non-myelinating SGCs were evident following repeated
morphine treatment at PID5 (Fig. 3B). By PID21, CXCR4 immunore-
activity (-IR) in the non-myelinating SGCs of the morphine treated
rats was again evident (Fig. 3C). Concurrent with return of CXCR4-
IR, SGCs in the DRG at PID21 was the gradual return of PWT to pre-
treatment BL thresholds (Fig. 2).3.3. SDF1 mRNA is increased in sensory neurons following repeated
morphine treatment and the protein is tonically released
Given the apparent decline of CXCR4-IR in the DRG following
the repeated morphine treatment paradigm, we determined
whether SDF1 mRNA expression in the lumbar DRG was also al-
tered by the dosing paradigm. We observed cellular expression
patterns of SDF1 mRNA transcripts by in situ hybridization using
digoxigenin-labeled riboprobes in relatively few cells of the sal-
ine-treated DRG (Fig. 4A). Following repeated morphine treatmentt of tactile hyperalgesia as measured by von Frey ﬁlaments. Tactile hyperalgesic
day, PID, post-injection day (one-way ANOVA; ⁄p < 0.05, signiﬁcant difference from
Fig. 3. Repeated morphine injections reduces CXCR4-immunoreactivity (-IR) in satellite glial cells of rat lumbar DRG sections. Animals received repeated morphine injections
(10 mg/kg for 5 days) and tissue was collected at 5 days (PID5) and 21 days (PID21) after the last morphine injection. (A) CXCR4-IR (red) is largely restricted to satellite glial
cells in the naïve rodent DRG. (B) Following repeated morphine treatment, CXCR4-IR is reduced at PID5. (C) By PID21 CXCR4-IR begins to return to naïve levels. Scale bar is
100 lm (n = 7 for day 5 and n = 7 for each day 21).
Fig. 4. SDF1 mRNA expression is increased in the lumbar DRG following repeated morphine exposure. In situ hybridization was used to assess the expression pattern of SDF1
mRNA. (A) High power photomicrograph of basal expression of SDF1 mRNA was observed in the lumbar DRG from saline injected rats in non-neuronal cells (black arrowhead
indicates SDF1 mRNA transcripts in non-neuronal cell). Teal arrows indicate a lack of neuronal SDF1 mRNA transcripts. After a repeated morphine exposure, the level of SDF1
mRNA expression increased by post-injection day (PID) -5. SDF1 mRNA expression appears in both neuronal and non-neuronal cells. (Black arrows indicate neurons positive
for SDF1 mRNA transcripts; arrowheads, presumptive glial cells positive for SDF1 mRNA transcripts). Scale bar A and B is 50 lm (n = 5 for each condition).
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SDF1 mRNA transcripts (Fig. 4B).
The observation that SDF1 is expressed in DRG neurons follow-
ing repeated morphine treatment raises the possibility that the li-
gand may be tonically released from these cells. We therefore
examined the release of SDF1 using the F11 cell line. This cell line
was derived from DRG neurons and maintains many of the differ-
entiated properties of these cells (Platika et al., 1985). We com-
pared the characteristics of SDF1 release to those of MCP1/CCL2,
another chemokine that has been shown to be expressed andFig. 5. Chemokine speciﬁc release from transfected F11 cells is by regulated (MCP1) or
then depolarized by high K stimulation (50 mM; 50 K), either with or without extracellu
medium was measured by sandwich ELISA. The release of SDF1-mRFP1 was examined in
in F11 cells prior to addition of 50 mM K were 6.3 ± 0.7% or 10 ± 1.1% of total media, resp
comparison test).released by DRG neurons (Jung et al., 2008). Following the expres-
sion of chemokine ﬂuorescent fusion proteins (SDF1-RFP and
MCP1-EGFP) we noted that the two chemokines localized to differ-
ent sets of secretory vesicles (Supplementary Fig. 1). We measured
constitutive and K+ depolarization induced release of each chemo-
kine from F11 cells using a sandwich ELISA, and observed that the
patterns of release for the two chemokines were also different. Re-
lease of MCP1-RFP from differentiated F11 cells was signiﬁcantly
increased by depolarizing medium containing high K+ (Fig. 5A).
However, the release of SDF1-RFP was quite apparent underconstitutive release mechanisms (SDF1). F11 DRG neurons were differentiated and
lar Ca (2 or 0 mM; 2Ca or 0Ca). The amount of MCP1-RFP released into the culture
the same manner as MCP1-mRFP1. Baseline levels of MCP1-RFP (A) or SDF1-RFP (B)
ectively (A sandwich ELISA; ⁄p < 0.01 vs. any other group, Newman–Keuls multiple
570 N.M. Wilson et al. / Brain, Behavior, and Immunity 25 (2011) 565–573non-depolarizing conditions and was not increased further by K+
depolarization (Fig. 5B), suggesting that most SDF1 release was
constitutive whereas signiﬁcant portion of MCP1 release was reg-
ulated by neuronal depolarization. This result implies that once
the expression of SDF1 has been increased in DRG neurons (see
Fig. 4), it will be constitutively released from these cells.
3.4. Repeated morphine treatment increases functional chemokine
receptor expression by capsaicin sensitive DRG neurons
To further investigate the status of functional CXCR4 receptor
expression in the DRG following repeated morphine treatment,
we utilized Ca2+ imaging studies in acutely dissociated DRGs de-
rived from animals subjected to repeated morphine conditions
and naïve controls. The time points used corresponded to time
points used for immunohistochemical and behavioral assessment
(Fig. 2). The acutely dissociated DRG preparations were categorized
into three neuronal and non-neuronal cell types: non-capsaicin
sensitive neurons (high K and ATP responsive), capsaicin sensitive
neurons (capsaicin, high K, and ATP responsive), and glia (ATP
responsive only). These cell response criteria were chosen strictly
as an indicator of the types of cells that may be affected by the re-
peated morphine treatment paradigm. The tested chemokines
were selected so as to activate a wide spectrum of chemokine
receptors known to be expressed by neurons and non-neuronal
cells (CXCR4-SDF1/CXCL12, CXCR3-IP10/CXCL10, CCR2-MCP1/
CCL2, CCR5-RANTES/CCL5). The chemokine concentration used
for these experiments were based on their maximally effective
concentrations using our previous observations on acutely dissoci-
ated DRGs (Bhangoo et al., 2007a,b).
Application of all tested chemokines produced [Ca2+]i changes
in small numbers of neuronal and non-neuronal populations of
cells derived from control DRGs (Table 1). Following exposure to
repeated morphine treatment, we observed a signiﬁcant increase
in the chemokine responsiveness of non-capsaicin sensitive and
capsaicin sensitive neurons. This included a robust increase in
SDF1 responsive capsaicin sensitive neurons (p < 0.0001). Hence
it appears that DRG nociceptive neurons express more functional
chemokine receptors, including CXCR4 receptors, following the re-
peated morphine treatment paradigm (Table 1).
3.5. Reduced CXCR4 expression following repeated morphine
treatment is abolished by AMD3100 treatment
Given that tonic activation of CXCR4 by SDF1 leads to internal-
ization of both chemokine and receptor (Burger and Kipps, 2006), it
is entirely possible that the constitutive release of neuronal SDF1
and subsequent neuronal signaling via CXCR4 may result in dimin-
ished evidence of CXCR4-IR in the sensory ganglia of morphine
treated rats (Fig. 6C). This event would not be unlike previous re-
ports in the dentate gyrus (Bhattacharyya et al., 2008; KolodziejTable 1
Repeated morphine treatment increases the percentage of nociceptive neurons that respon
morphine injections (10 mg/kg for 5 days) were administered to animals. Lumbar DRG







SDF1 7% (6/85) 7% (5/72) 21% (9/44
IP10 4% (3/85) 0% (0/72) 2% (1/44)
MCP1 4% (3/85) 6% (4/72) 9% (4/44)
RANTES 14% (12/85) 4% (6/72) 21% (9/44
* p < 0.05, v2 with Yates correction.
** p < 0.001, v2 with Yates correction.et al., 2008). Additional studies have shown that the binding capa-
bilities of the CXCR4 antibody utilized for these studies can com-
pete with SDF1 binding sites (Dubeykovskaya et al., 2009). To
test this possibility we intraperitoneally administered the CXCR4
antagonist, AMD3100, at doses of 1 and 10 mg/kg and sacriﬁced
the animals 1 h later. Overall increases in CXCR4-IR binding were
observed following AMD3100 administration in morphine-treated
animals at 10 mg/kg (Fig. 6E), but not 1 mg/kg (Fig. 6D). As evi-
dence of the de novo SDF1 signaling via CXCR4, CXCR4-IR was also
observed in numerous neurons (Fig. 6E). This data provides further
support for the increased functional CXCR4 receptors observed in
neurons (see Table 1). Three hours after AMD3100 administration,
the CXCR4-IR was again qualitatively decreased in the DRG
(Fig. 6F). Following administration of AMD3100 in the naïve animal
(Fig. 6B), there was a noticeable decrease in CXCR4-IR when com-
pared with the naïve animal (Fig. 6A). This is likely attributed to
the competition that exists between AMD3100 and CXCR4 anti-
body for available receptor binding sites.
3.6. Decreased tactile hyperalgesia following intraperitoneal injection
of CXCR4 antagonist, AMD3100
To determine whether SDF1/CXCR4 signaling was involved in
OIH, we administered a single systemic dose of either vehicle or
10 mg/kg AMD3100 i.p. at PID5. Systemic injection of AMD3100
(10 mg/kg) in naïve rodents did not alter baseline PWT
(70.5 ± 2.1 mN; Fig. 7). Vehicle injections in morphine treated rats
did not alter PWT (data not shown). However, 1 h after AMD3100
was administered to morphine treated rats, PWT returned to base-
line (69.25 ± 2.75 mN; p < 0.01). The rapid onset of AMD3100 was
short lived as PWTs returned to predosing levels by three hours
(35.25 ± 4.59 mN) (Fig. 7). The return of morphine-induced behav-
ior 3 h post AMD3100 injection coincides with the returned loss of
CXCR4-IR observed 3 h post AMD3100 injection in rat DRG sections
(Fig. 6F).
4. Discussion
The experiments reported here demonstrate that following re-
peated morphine exposure, rodents exhibited a prolonged tactile
hyperalgesia. This change in paw withdrawal threshold was main-
tained at least until PID28. Importantly, morphine-induced tactile
hyperalgesia could be transiently reversed by a chemokine recep-
tor antagonist that is speciﬁc for CXCR4 receptors. These results
provide the ﬁrst demonstration that morphine-induced tactile
hyperalgesic behavior in the rodent appears to be dependent on
activation of CXCR4 receptors. Thus, morphine induced SDF1 sig-
naling via CXCR4 receptors appears to change the balance between
opioid analgesia and hyperalgesia.
OIH has been observed both clinically (Angst et al., 2003; Arner
et al., 1988; Singla et al., 2007) and experimentally (Laulin et al.,d to chemokine administration as indicated by a change in intracellular calcium. Daily
were acutely dissociated from these animals 4–6 days following the last morphine







) 15% (17/112) 34% (25/73) ** 27% (13/49)
13% (14/112)* 25% (18/73) ** 8% (4/49)
16% (18/112) ** 29% (21/73) ** 25% (12/49)
) 17% (19/112) 29% (21/73) ** 12% (6/49)
Fig. 6. The CXCR4 antagonist AMD3100 reverses loss of CXCR4 immunoreactivity in DRG derived from repeated morphine treated rats. Untreated rats (A), naïve animal
administered AMD3100 1 h before sacriﬁce (B), repeated morphine treatment alone (i.p., 10 mg/kg, once daily for 5 days) (C) repeated morphine treatment in combination
with different doses of AMD3100 1 h before sacriﬁce (D and E) and 3 h before sacriﬁce (F). Treatment with AMD3100 reverses repeated morphine treatment-induced loss of
CXCR4 immunoreactivity at PID5 (C) in a dose-dependent manner (D and E). CXCR4-immunoreactivity (red label) in rat DRG sections following 10 mg/kg (E), but not 1 mg/kg
(D) dose of AMD3100 returns CXCR4 immunoreactivity to levels observed in untreated control rats (A). White arrows indicate the presence of CXCR4-immunopositive
neurons following AMD3100 treatment. Scale bar is 100 lm.
Fig. 7. Morphine-induced tactile hyperalgesia in rodents is transiently reversed with CXCR4 antagonist, AMD3100 treatment. Five days following the last morphine injection
(PID5) rats received an i.p. injection of AMD3100 (10 mg/kg) and tactile behavior was measured by von Frey ﬁlaments 1 and 3 h post-injection. AMD3100 treatment
completely reversed morphine-induced tactile hyperalgesia by 1 h post-injection. Tactile hyperalgesia returned 3 h following injection of AMD3100. ⁄Signiﬁcant difference
from baseline; one-way ANOVA; p < 0.01).
N.M. Wilson et al. / Brain, Behavior, and Immunity 25 (2011) 565–573 5711999; Woolf, 1981). Many explanations for this phenomenon have
been suggested which have centered largely on changes within the
central nervous system. These potential mechanisms include en-
hanced production/release of glutamate and neuropeptides in the
spinal cord (Belanger et al., 2002; Ibuki et al., 2003; Mao et al.,2002), protein kinase C c-induced signaling (Lim et al., 2005),
spinal Ca2+/calmodulin-dependent protein kinase II a activity
(Chen et al., 2010), enhanced descending facilitation of nociceptive
pathways from the rostral ventromedial medulla (Vanderah et al.,
2001) and activation of non-classical opioid receptors (Lewis et al.,
572 N.M. Wilson et al. / Brain, Behavior, and Immunity 25 (2011) 565–5732010). Alternative peripheral mechanisms also include sensitiza-
tion of peripheral nociceptors (Aley and Levine, 1997; Liang
et al., 2008).
The mechanisms responsible for morphine induced SDF1/
CXCR4 signaling in primary sensory neurons of the DRG are largely
unknown. Thus, the effects we have observed might be down-
stream of morphine’s interactions with l-opioid receptors or pos-
sibly through interactions with TLR4 as has been recently
suggested (Hutchinson et al., 2010). A number studies have been
conducted demonstrating the ability of chemokines and opioid
agonists administration to induce heterologous desensitization to
their respective systems (Szabo et al., 2002, Chen et al., 2007).
These studies have clearly shown that there is a relationship be-
tween the chemokine and opioid signaling pathways during acute
administration. However, our results expand on these studies by
suggesting that following the chronic administration of morphine
produces an alteration in sensory neuron SDF1/CXCR4 signaling
that lasts for at least 5 days after the last opioid injection.
With respect to morphine induced changes in CXCR4 activation,
there appear to be two important changes in the status of SDF1/
CXCR4 signaling within the DRG. First, it appears that greater
CXCR4 signaling occurs following the dosing regimen. This is indi-
cated by the fact that during OIH there is an AMD3100 reversible
decline in CXCR4-IR in the DRG, presumably resulting from SDF1
activation of CXCR4 receptors followed by their internalization
and recycling mechanisms, as previously observed in the dentate
gyrus (Bhattacharyya et al., 2008; Kolodziej et al., 2008). Secondly,
the increased SDF1/CXCR4 activation could result from enhanced
tonic release of neuronal SDF1 whose expression was upregulated
under these conditions, or some postsynaptic effect of morphine
which produces enhanced CXCR4 desensitization in response to
tonically released SDF1. In particular, the Ca2+ imaging experi-
ments and the immunohistochemistry studies following
AMD3100 administration clearly demonstrate that morphine
treatment results in considerable degree of upregulated expression
of CXCR4 by DRG nociceptors. Our results highlight the rapid time
course of CXCR4 down-regulation and recycling that occurs in the
DRG and other cell types. Numerous studies have demonstrated
that the time course and extent of CXCR4 recycling in different cell
types is subject to a very large number of factors that can interact
with the receptor and regulate the different stages of endocytosis,
and recycling or degradation (Tarasova et al., 1998; Zhang et al.,
2004). Thus it is becoming clear that regulating the levels of CXCR4
cell surface expression is one important mechanism of adjusting
the signaling possibilities through this pathway. As activation of
chemokine receptors expressed by DRG neurons produces excita-
tion (White et al., 2007), it is likely the activation of these receptors
by SDF1 contributes to the ectopic excitability of these neurons
and produces AMD3100 reversible tactile hyperalgesia. The tran-
sient effect of AMD3100 may be explained by the short half life
of 0.9 h following a single administration (Hendrix et al., 2000).
To this end, our observations support the growing body of litera-
ture that chemokines can act as neurotransmitters under some cir-
cumstances (White et al., 2007).
In the case of SDF1, its release mechanism may be unusual as it
does not seem to require a depolarization induced increase in Ca2+,
in contrast to the depolarization dependent release of MCP1. The
different release mechanisms may be due to the observation that
the two chemokines appear to be stored in separate subcellular
compartments. Thus, it is possible that the SDF1 storage vesicles
may be released by lower levels of Ca2+ or by low Ca2+ in coopera-
tion with some other signaling mechanism. We demonstrated that
morphine will increase the expression of SDF1 within DRG
neurons. According to our data increased concentrations of SDF1
within DRG neurons should result in increased tonic release of
the chemokine. The fact that appreciable levels of SDF1 may betonically released both in the DRG (data herein) and the dentate
gyrus suggest that SDF1 may generally be secreted in this way
when utilized in the nervous system (Bhattacharyya et al., 2008;
Kolodziej et al., 2008). Until recently, CXCR4 was known to be
the only receptor for SDF1. This idea was challenged when the che-
mokine receptor, CXCR7, was shown to bind SDF1 (Balabanian
et al., 2005). Initially described as a scavenger receptor, more re-
cent interactions describe CXCR7 as possibly moderating the re-
sponse of CXCR4 to SDF1 by internalizing the ligand (Zabel et al.,
2009). Whether SDF1/CXCR7 activation serves to modulate OIH is
unknown. However, we have observed that CXCR7 is expressed
in the DRG of adult mice (unpublished observations) and so this re-
mains a possibility.
In conclusion, ongoing SDF1/CXCR4 signaling within sensory
neurons provides a mechanistic basis for understanding OIH mod-
iﬁcations within the nervous system. Beyond its signaling rele-
vance in the sensory neuron, the relationship between neuronal
expression of SDF1/CXCR4 and tactile hyperalgesia in the rodent
may imply that chemokine-sensitized sensory neurons may serve
as an excitatory signal central to OIH. Thus, OIH represents another
example of chronic pain behavior where chemokine signaling in
DRG neurons has been observed to be upregulated (White et al.,
2009), further highlighting the potential role of chemokine signal-
ing in the generation of chronic pain.
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